Matthew Kaplan

Stock Analyst at Ladenburg Thalmann

(2.81)
# 1,674
Out of 5,123 analysts
26
Total ratings
62.5%
Success rate
19%
Average return

Stocks Rated by Matthew Kaplan

United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319$344
Current: $478.93
Upside: -28.17%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48$54
Current: $20.51
Upside: +160.85%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39$40
Current: $27.76
Upside: +44.09%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15$30
Current: $41.56
Upside: -27.82%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5$8.5
Current: $7.00
Upside: +21.43%
Avadel Pharmaceuticals
May 2, 2023
Maintains: Buy
Price Target: $15$16
Current: $21.60
Upside: -25.93%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.12
Upside: +50,418.87%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340$460
Current: $1.05
Upside: +43,919.14%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $7.72
Upside: +560.62%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $35.70
Upside: -55.18%
Initiates: Buy
Price Target: $45
Current: $6.50
Upside: +592.31%